Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Extensive-Stage Small Cell Lung Cancer

• Sponsor: Hutchison Medipharma Limited (Industry)
• Overall Status: Not yet recruiting
• CT.gov ID: NCT05509699
• Collaborator: (none)
• Enrollment: 60
• Location: 1
• Arms: 2
• Anticipated Duration (Months): 28
• Patients Per Site Per Month: 2.1

Study Details

Study Description

Brief Summary

This is an open-label, multi-center Phase II study designed to evaluate the efficacy and safety of Surufatinib plus anti-PD-1/L1 as maintenance therapy after first-line standard of care in patients with ES-SCLC.

Condition or Disease	Intervention/Treatment	Phase
Extensive-Stage Small Cell Lung Cancer	Drug: Surufatinib; Drug: Anti-PD-1/L1	Phase 2

Detailed Description

This study consists of two parts, i.e., a single-arm Phase IIa study and a randomized, controlled Phase IIb study. All the enrolled patients will be patients with ES-SCLC who did not have PD (determined as per the RECIST v1.1) after prior platinum-based chemotherapy in combination with an anti-PD-1/L1. Approximately 20 patients are planned to be enrolled in the single-arm Phase IIa study to preliminarily observe the efficacy and safety. Approximately 40 patients are planned to be enrolled in the randomized and controlled Phase IIb study with 20 patients per group.

Study Design

• Study Type: Interventional
• Anticipated Enrollment: 60 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Intervention Model Description: The study consists of two parts, i.e., a single-arm Phase IIa study and a randomized (1:1), controlled Phase IIb study. Phase IIa: It is planned that 20 patients will be enrolled to receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy . Phase IIb: It is planned that 40 patients will be enrolled to receive the following treatments: Group A: Patients will receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy. Group B: Patients will receive treatment with anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy.The study consists of two parts, i.e., a single-arm Phase IIa study and a randomized (1:1), controlled Phase IIb study.Phase IIa:It is planned that 20 patients will be enrolled to receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy .Phase IIb:It is planned that 40 patients will be enrolled to receive the following treatments:Group A: Patients will receive treatment with Surufatinib plus anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy. Group B: Patients will receive treatment with anti-PD-1/L1, the same immune checkpoint inhibitor from patients' first-line therapy.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: An Open-Label, Multi-Center Phase II Study of Surufatinib Plus Anti-PD-1/L1 as Maintenance Therapy in Patients With Extensive-Stage Small Cell Lung Cancer
• Anticipated Study Start Date: Aug 1, 2022
• Anticipated Primary Completion Date: Apr 1, 2024
• Anticipated Study Completion Date: Dec 1, 2024

Arms and Interventions

Arm	Intervention/Treatment
Experimental: Surufatinib in combination with anti-PD-1/L1 therapy Surufatinib 250 mg orally once plus anti-PD-1/L1, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.	Drug: Surufatinib; The recommended dosage is 250 mg orally once daily (QD) within 1 hour after breakfast for continuous administration.; Drug: Anti-PD-1/L1; Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.; Other Names: Immune checkpoint inhibitor
Experimental: Anti-PD-1/L1 monotherapy Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy	Drug: Anti-PD-1/L1; Anti-PD-1/L1 therapy, Q3W or Q4W, the same immune checkpoint inhibitor from patients' first-line therapy.; Other Names: Immune checkpoint inhibitor

Outcome Measures

Primary Outcome Measures

1. Progression-free survival [About 18 months]

   Progression-free survival(PFS) assessed by the investigator as per the Response Evaluation Criteria in Solid Tumors v1.1 (RECIST v1.1)

Secondary Outcome Measures

1. Overall survival [About 18 months]

   Overall survival (OS)

2. Objective response rate [About 18 months]

   Objective response rate (ORR) assessed per RECIST v1.1

3. Disease control rate [About 18 months]

   Disease control rate (DCR) assessed per RECIST v1.1

4. Duration of response [About 18 months]

   Duration of response (DoR) assessed per RECIST v1.1

Eligibility Criteria

Criteria

• Ages Eligible for Study: 18 Years to 75 Years
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Inclusion Criteria:

1. Patients who sufficiently understand this study and is willing to sign the ICF;

2. Aged from 18 to 75 years (inclusive);

3. Patients with histologically or cytologically confirmed ES-SCLC ;

4. Patients who did not have PD (assessed as per the RECIST v1.1) after prior first-line platinum-based chemotherapy plus an anti-PD-1/L1;

5. Patients with measurable lesions as defined in the RECIST v1.1 ;

6. Life expectancy ≥ 12 weeks;

7. Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 to 1;

8. Adequate organ function:

9. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to the first dose. Male or female patients of childbearing potential should be willing to use effective contraceptive methods during the study and within 90 days after last dose of the study drug.

Exclusion Criteria:

1. Previous use of anti-vascular endothelial growth factor (VEGF) drugs/anti-vascular endothelial growth factor receptor (VEGFR) agents;

2. Use of systematic anti-tumor therapies other than first-line platinum-based chemotherapy in combination with anti-PD-1/L1 within 4 weeks prior to the first dose;

3. Presence of central nervous system (CNS) metastasis and/or cancerous meningitis (metastases to meninges);

4. Toxicities associated with previous anti-tumor treatment that has not been resolved to CTCAE Grade ≤ 1, except for alopecia and CTCAE Grade ≤ 2 peripheral neurotoxicity;

5. Uncontrollable malignant hydrothorax, ascites or pericardial effusion;

6. Patients with active autoimmune disorder or immunodeficiency or history of autoimmune disorder or immunodeficiency;

7. Patients with evidence or history of obvious bleeding tendency within 2 months prior to the first dose;

8. Clinically significant cardiovascular disorders;

9. Severe infection within 4 weeks prior to the start of study treatment, including but not limited to hospitalization for infection, bacteraemia or severe pneumonia;

10. Patients who are unable to take oral medications, or with previous surgical history or severe gastrointestinal;

11. Pregnant (with a positive pregnancy test) or lactating women within 5 years before screening.

12. Patients with a history of malignant tumors excluding small cell lung cancer (SCLC) within 5 years before screening.

Contacts and Locations

Locations

	Site	City	State	Country	Postal Code
1	Chinese PLA General Hospital	Beijing		China

Sponsors and Collaborators

• Hutchison Medipharma Limited

Investigators

• Principal Investigator: Yi Hu, Postdoctor, Chinese PLA General Hospital

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.

• Responsible Party: Hutchison Medipharma Limited
• ClinicalTrials.gov Identifier: NCT05509699
• Other Study ID Numbers: 2022-012-00CH1
• First Posted: Aug 22, 2022
• Last Update Posted: Aug 22, 2022
• Last Verified: Aug 1, 2022

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No
• Product Manufactured in and Exported from the U.S.: No
• Additional relevant MeSH terms: Lung Neoplasms; Small Cell Lung Carcinoma; Immune Checkpoint Inhibitors

Study Results

No Results Posted as of Aug 22, 2022